Table 1.
Participant characteristics of samples analyzed with luminex compared to the whole cohort.
| Luminex cohort (N = 149) | AB– (N = 95) | AB+ (N = 54) | INCA clinical cohort (N = 436) | ||
|---|---|---|---|---|---|
| Gender | Male (%) | 90 (60.4%) | 56 (58.9) | 34 (63.0) | 237 (54.4%) |
| Gestational age | (SD) | 39.7 (1.5) | 39.4 (1.5) | 40.0 (1.2) | 39.7 (1.5) |
| Birthweight | (SD) | 3,552 (544) | 3,465 (557) | 3,707 (489) | 3,526 (546) |
| Delivery mode | Vaginal (%) | 111 (74.5%) | 68 (71.6) | 43 (79.6) | 599 (68.6%) |
| Breastfed exclusive | 0 months (%) | 33 (22.1%) | 42 (44.2) | 31 (57.4) | 99 (22.7%) |
| 1–3 months | 63 (42.3%) | 26 (27.4) | 7 (13.0) | 181 (41.5%) | |
| >3 months | 53 (35.6%) | 27 (28.4) | 16 (29.7) | 156 (35.8%) | |
| Antibiotics (< day 7) | (%) | 54 (36.2%) | 151 (34.6%) | ||
| Infantile colic | (%) | 26 (17.4%) | 14 (14.7) | 12 (22.2) | 74 (17.0%) |
| Eczema | (%) | 20 (13.4%) | 15 (15.8) | 5 (9.3) | 58 (13.3%) |